Shares of ClearOne (CLRO) swung sharply higher on August 7, trading at $4.57, up nearly 12% intraday, even as the stock remains well below its early-July highs — a sign that investors are still wrestling with the implications of a transformative but risky merger. ClearOne's Cortigent Merger Promises a Medical-Tech Makeover — But Can Legacy Shareholders Survive the Dilution Math?
Shares of ClearOne (CLRO) bounced 11.9% to $4.57 on August 7, a volatile snap-back in a stock that has shed more than half its value since spiking above $8 in early July. The catalyst remains the same: a July 1 merger agreement that will transform a struggling audio-equipment maker into a clinical-stage medical-device company — at an enormous cost to existing owners.
• The Deal Swaps Identity but Hands the Keys to a New Owner. ClearOne agreed to merge Cortigent, a Vivani Medical subsidiary developing precision neurostimulation implants, into a wholly owned ClearOne subsidiary, with Vivani receiving 12.5 million new ClearOne shares and becoming majority owner.
ClearOne will be renamed "Cortigent Holdings, Inc" and is expected to trade under Nasdaq ticker symbol "CRGT."
Post-transaction shares are projected at roughly 16 million, with Vivani holding about 78%, existing ClearOne stockholders about 16.7%, and advisors about 5.3%. In plain terms, current CLRO holders keep roughly one-sixth of the company they once fully owned.
• A $10–15 Million Stock Offering Adds Another Layer of Dilution. The planned financing involves 2.5–5 million units — each bundled with stock and $10 warrants — raising $10–15 million but introducing further dilution for ClearOne holders. That cash is essential to fund Cortigent's neurostimulation research, but every new share printed shrinks legacy owners' slice further.
• ClearOne's Current Business Is Burning Cash, Not Generating It. Q1 2026 financials showed negative EBITDA of -$314,000, gross losses, and free cash flow of -$680,000.
With less than a year's worth of cash, the company needs to raise capital or take on debt. The merger isn't optional — it's a lifeline away from what one filing called a "non-growth runoff posture."
• Recent Moves Show the Clock Is Ticking Toward Closing. On August 4, ClearOne cancelled 437,500 warrants at $5.00 per share held by First Finance Ltd., a major shareholder controlling about 61.3% of voting power, who has already given written consent to the deal.
The company plans to complete these actions no earlier than 20 calendar days after mailing its information statement to shareholders of record as of July 31. That puts the earliest possible closing in late August, consistent with the Q3 2026 target.
Today's bounce doesn't change the fundamental equation: investors are betting a pre-revenue brain-implant company will be worth more than the ownership they're giving up.